Cetera Trust Company, N.A Halozyme Therapeutics, Inc. Transaction History
Cetera Trust Company, N.A
- $167 Billion
- Q2 2025
A detailed history of Cetera Trust Company, N.A transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cetera Trust Company, N.A holds 6,200 shares of HALO stock, worth $427,676. This represents 0.19% of its overall portfolio holdings.
Number of Shares
6,200
Previous 5,775
7.36%
Holding current value
$427,676
Previous $369 Million
12.48%
% of portfolio
0.19%
Previous 0.23%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
605Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.22 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$845 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$409 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$239 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$234 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.61B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...